The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

The U.S. Food and Drug Administration (FDA) approved the antidepressant nasal spray Spravato as a standalone treatment for depression in adults.

The FDA’s latest approval of the nasal spray Spravato (esketamine) CIII marks a major shift in how major depressive disorder is managed, allowing people who have tried at least two oral ...

If we take Allan Walsh’s words into account, it could really be different starting from the 27-28 season. The player agent talked about it on his podcast last week, and Elliotte Friedman shared his ...

Twenty-one patients (35%) achieved remission with 8 of the 21 patients (38%) needing the 50 mg dose to achieve remission. Median time to remission was 24 weeks and median dose in remission was 30 mg.

A thief smashed their way into a Sutton Coldfield shop and stole Lego sets potentially worth thousands of pounds. It happened at the Toys4You shop in the Parade shortly after midnight today ...

Life Kit is here to help you get it together. Want another life hack? Try Life Kit+. You'll support the show and unlock exclusive curated playlists and sponsor-free listening. Learn more at plus ...

Your doctor will likely have you start treatment with a 2.5-mg dose of Mounjaro. After 4 weeks of treatment, they’ll increase your dose to 5 mg per week. Starting with a lower dose helps your ...

At that time point, 22% of patients given a 28 mg dose of the drug and 24% of those on a 50 mg dose reached that level of improvement, compared to 14% of the placebo group, with the differences ...